Combination immunotherapy for the treatment of cancer
Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
1. A method of treating cancer in a patient comprising administering to the patient a blocking anti-PD-1 antibody and an agonist anti-ICOS antibody.
2. The method of claim 1 , wherein the blocking anti-PD-1 antibody and the agonist anti-ICOS antibody are administered simultaneously or sequentially.
3. The method of claim 1 , wherein the agonist anti-ICOS antibody is a monoclonal antibody.
4. The method of claim 3 , wherein the blocking anti-PD-1 antibody is a monoclonal antibody.
5. The method of claim 4 , wherein the agonist anti-ICOS antibody is a humanized antibody.
6. The method of claim 3 , wherein the blocking anti-PD-1 antibody is a humanized antibody.
7. The method of claim 1 , wherein the agonist anti-ICOS antibody is a humanized antibody.
8. The method of claim 7 , wherein the blocking anti-PD-1 antibody is a humanized antibody.
9. The method of claim 1 consisting of administering to the patient one or more doses of the blocking anti-PD-1 antibody and one or more doses of the agonist anti-ICOS antibody.
10. The method of claim 9 , wherein at least one dose of the blocking anti-PD-1 antibody and at least one dose of the agonist anti-ICOS antibody are administered simultaneously or sequentially.
11. The method of claim 9 , wherein the agonist anti-ICOS antibody is a monoclonal antibody.
12. The method of claim 11 , wherein the blocking anti-PD-1 antibody is a monoclonal antibody.
13. The method of claim 12 , wherein the agonist anti-ICOS antibody is a humanized antibody.
14. The method of claim 11 , wherein the blocking anti-PD-1 antibody is a humanized antibody.
15. The method of claim 9 , wherein the agonist anti-ICOS antibody is a humanized antibody.
16. The method of claim 15 , wherein the blocking anti-PD-1 antibody is a humanized antibody.
17. The method of claim 4 , wherein the method does not comprise administering another antitumor treatment.
18. The method of claim 4 , wherein the method does not comprise administering another antitumor treatment other than surgical resection or radiation therapy.
19. The method of claim 4 , wherein the method does not comprise administering another immunotherapy.